Drug or technology
7 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
AUG 4, 2026 · PHASE 1 TRIAL
ClinicalTrials.gov
Phase 1 dose-escalation trial with completed enrollment but no efficacy or safety results reported in this registry record; evidence of tolerability and MTD cannot be assessed without posted outcomes.
JUL 22, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of labeling changes for lenalidomide; describes a regulatory action, not clinical trial evidence or efficacy data.
APR 27, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for lenalidomide; does not contain clinical trial data or efficacy evidence.
APR 27, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a risk evaluation and mitigation strategy (REMS) for an existing drug; this is an administrative action, not a clinical evidence record.
APR 27, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for lenalidomide; this is a regulatory action, not a clinical trial, and does not report efficacy or comparative outcomes.
APR 27, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for lenalidomide; this is a regulatory action, not a clinical trial, and does not report efficacy or comparative clinical outcomes.
APR 27, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a REMS (Risk Evaluation and Mitigation Strategy) for lenalidomide generic formulations; does not report clinical trial data or efficacy evidence.